Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019

Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1174-1178. doi: 10.2215/CJN.05170420. Epub 2020 May 18.


Background and objectives: Outcomes of kidney transplant recipients diagnosed with coronavirus disease 2019 as outpatients have not been described.

Design, setting, participants, & measurements: We obtained clinical data for 41 consecutive outpatient kidney transplant recipients with known or suspected coronavirus disease 2019. Chi-squared and Wilcoxon rank sum tests were used to compare characteristics of patients who required hospitalization versus those who did not.

Results: Of 41 patients, 22 (54%) had confirmed coronavirus disease 2019, and 19 (46%) were suspected cases. Patients most commonly reported fever (80%), cough (56%), and dyspnea (39%). At the end of follow-up, 13 patients (32%) required hospitalization a median of 8 days (range, 1-16) after symptom onset, and 23 (56%) had outpatient symptom resolution a median of 12 days (4-23) after onset. Patients who required hospitalization were more likely to have reported dyspnea (77% versus 21%, P=0.003) and had higher baseline creatinine (median, 2.0 versus 1.3 mg/dl, P=0.02), but there were no other differences between groups.

Conclusions: In an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, many had symptomatic resolution without requiring hospitalization.

Keywords: COVID-19; Cohort Studies; Dyspnea; Nonparametric; Outpatients; SARS-CoV2; Statistics; coronavirus; creatinine; hospitalization; kidney transplantation; severe acute respiratory syndrome coronavirus 2.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / therapy*
  • Dyspnea / therapy
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Outpatients
  • Pandemics
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2


  • Immunosuppressive Agents